Evidence map›Paper›PMID 30404587›Full record

ArticleCancer biology & therapy2019

Knockdown of linc00152 inhibits the progression of gastric cancer by regulating microRNA-193b-3p/ETS1 axis.

Haifang Wang, Wenxiang Chen, Peng Yang, Jun Zhou, Kaiyuan Wang, Qingchun Tao

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Cells · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Haifang Wanga Department of Chinese and Western Integrative Medicine and Department of Clinical Laboratory , Beijing University of Chinese Medicine Third Affiliated Hospital , Beijing , China.
Wenxiang Chenb Department of Spine Orthopaedics , Liaocheng Traditional Chinese Medicine hospital , Liaocheng , China.
Peng Yanga Department of Chinese and Western Integrative Medicine and Department of Clinical Laboratory , Beijing University of Chinese Medicine Third Affiliated Hospital , Beijing , China.
Jun Zhoua Department of Chinese and Western Integrative Medicine and Department of Clinical Laboratory , Beijing University of Chinese Medicine Third Affiliated Hospital , Beijing , China.
Kaiyuan Wangc Chinese Medical Department of Internal respiration , Dongzhimen Hospital, Beijing University of Chinese Medicine , Beijing , China.
Qingchun Taod Department of Clinical Laboratory , Beijing University of Chinese Medicine Third Affiliated Hospital , Beijing , China.
Beijing University of Chinese Medicine · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNLiaocheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer (GC) is a serious threat for public health worldwide. Long non-coding RNA (lncRNA) linc00152 has been well reported to be an oncogene and a potential biomarker in multiple cancers including GC. However, the molecular mechanisms of linc00152 in GC development need to be further investigated.

methodsRT-qPCR assay was employed to detect the levels of linc00152, microRNA-193b-3p (miR-193b-3p) and ETS1 mRNA. ETS1 protein level was measured by western blot assay. Cell proliferative, migratory and invasive capacities were assessed by colony formation together with CCK-8 assays, transwell migration and invasion assays, respectively. Bioinformatics analyses and luciferase reporter assay were used to explore whether miR-193b-3p could interact with linc00152 or ETS1 3'UTR. The roles and molecular basis of linc00152 silence on the growth of GC xenograft tumors were tested in vivo.

resultsLinc00152 expression was notably upregulated in GC tissues and cells. The proliferative, migratory and invasive abilities of GC cells were weakened by linc00152 depletion, miR-193b-3p overexpression or ETS1 knockdown. Linc00152 upregulation inhibited miR-193b-3p expression by direct interaction and abolished miR-193b-3p-mediated anti-proliferation, anti-migration and anti-invasion effects in GC cells. ETS1 was a target of miR-193b-3p and linc00152 could promote ETS1 expression by downregulating miR-193b-3p. In vivo experiments further validated that linc00152 knockdown inhibited the growth of GC xenograft tumors by upregulating miR-193b-3p and downregulating ETS1.

conclusionKnockdown of linc00152 inhibited GC progression by sequestering miR-193b-3p from ETS1 in vitro and in vivo, elucidating a novel molecular mechanism of linc00152 in promoting GC carcinogenesis.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCell ProliferationFemaleHumansMiceMice, Inbred BALB CMice, NudeMicroRNAsPrognosisProto-Oncogene Protein c-ets-1RNA, Long NoncodingStomach NeoplasmsSurvival RateBiomarkers, TumorETS1 protein, humanlong non-coding RNA Linc00152, humanMicroRNAsMIRN193 microRNA, humanProto-Oncogene Protein c-ets-1RNA, Long NoncodingETS1gastric cancerlinc00152microRNA-193b-3p

Identifiers

PMID30404587
PMCPMC6422511
OpenAlexW2899639875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.